Monoclonal antibodies against human CD34 antigens do not cross-react with ovine umbilical cord blood cells

Bonelli, Piero; Nicolussi, Paola; Manetti, Roberto; Antuofermo, Elisabetta; Dattena, Maria
February 2010
Italian Journal of Animal Science;Feb2010, Vol. 9 Issue 1, p26
Academic Journal
CD34 is a cell surface glycoprotein expressed by hematopoietic progenitors and endothelial cells. It is widely used in the clinic for isolation of human hematopoietic stem cells. In recent years large animals are gaining increasing importance in biomedical research for the study and therapy of human diseases. Sheep has proved to be an useful experimental model for preclinical trials in transplantation procedures. Unfortunately, the lack of specie-specific monoclonal antibodies (MABS) recognizing hemopoietic progenitor cells hampers the use of this animal in experimental hematology. The aim of this paper was to determine whether commercial monoclonal antibodies specific for human CD34 molecule could cross-react with hematopoietic progenitor cells (HPC) present in sheep umbilical cord blood (UCB). Six antihuman CD34 MABS, recognizing the three different epitope classes, were tested in flow cytometry on purified mononuclear cells (MNC) isolated from cord blood of both species. None of the MABS used in this trial seemed to be able to identify HPC from sheep UCB. These data suggest that the panel of monoclonal antibodies used for cross reactivity detection has to be expanded with recently produced reagents. Further studies should be directed towards the production of ovine specific anti CD34 MABS.


Related Articles

  • Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Binétruy-Tournaire, Roselyne; Demangel, Caroline; Malavaud, Bernard; Vassy, Roger; Rouyre, Sylvie; Kraemer, Michel; Plouët, Jean; Derbin, Claude; Perret, Gérard; Mazié, Jean Claude // EMBO Journal;4/1/2000, Vol. 19 Issue 7, p1525 

    Vascular endothelial growth factor (VEGF) binding to the kinase domain receptor (KDR/FLK1 or VEGFR-2) mediates vascularization and tumor-induced angiogenesis. Since there is evidence that KDR plays an important role in tumor angiogenesis, we sought to identify peptides able to block the VEGF-KDR...

  • Therapeutics: Two for one. Seton-Rogers, Sarah // Nature Reviews Cancer;May2009, Vol. 9 Issue 5, p316 

    The article discusses a research on binding two protein antigens using a monoclonal antibody. It references a study by J. Bostrom et al published in the 2009 issue of "Science." The team by Germaine Fuh studied the monoclonal antibody trastuzumab that can bind two different cancer-related...

  • Imbalance of mononuclear cell infiltrates in the placental tissue from foetuses after spontaneous abortion versus therapeutic termination from 8th to 12th weeks of gestational age. Lambropoulou, M.; Tamiolakis, D.; Venizelos, J.; Liberis, V.; Galazios, G.; Tsikouras, P.; Karamanidis, D.; Petrakis, G.; Constantinidis, T.; Menegaki, M.; Papadopoulos, N. // Clinical & Experimental Medicine;Dec2006, Vol. 6 Issue 4, p171 

    Placental macrophages (Hofbauer cells) are located close to trophoblastic cells and foetal capillaries, which make them perfect candidates for involvement in regulatory processes within the villous core. Their capacity of producing several cytokines and prostaglandin-synthesising enzymes, and...

  • Resistance—the true face of biological defiance. Emami-Shahri, Nia; Hagemann, Thorsten // Rheumatology;Mar2012, Vol. 51 Issue 3, p413 

    Biological therapeutics are widely used in chronic inflammatory and malignant disease. The underlying mechanisms of treatment failure for these drugs are poorly understood. Resistance to these biological agents and the further subdivision into intrinsic and acquired resistance are not clearly...

  • Ranibizumab. Blick, Stephanie K.A.; Keating, Gillian M.; Wagstaff, Antona J. // Drugs;2007, Vol. 67 Issue 8, p1199 

    â–´ Ranibizumab is the antigen-binding fragment of a recombinant, humanised monoclonal antibody, which binds with high affinity to, and inhibits the activity of, all active forms of vascular endothelial growth factor A, an important mediator in the development of choroidal...

  • Antisense Oligodeoxynucleotide Against Tissue Factor Inhibits Human Umbilical Vein Endothelial Cells Injury Induced by Anoxia-Reoxygenation. Jun Yin; Xin Guo Luo; Wen Jun Yu; Jing Yuan Liao; You Jin Shen; Ze Wen Zhang // Cellular Physiology & Biochemistry (Karger AG);2010, Vol. 25 Issue 4/5, p477 

    Aims: The role of antisense oligodeoxynucleotide against tissue factor (aODN/TF) in cultured human umbilical vein endothelial cells (HUVECs) subjected to anoxia-reoxygenation (A/R) was investigated. Methods: HUVECs were divided randomly into control group, A/R group, aODN/TF+A/R group, sense...

  • Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents. Stewart, Keri S.; Kleinerman, Eugenie S. // Sarcoma;2011, p1 

    Ewing's sarcoma accounts for a disproportionately high portion of the overall pediatric mortality rate compared to its rare incidence in the pediatric population. Little progress has been made since the introduction of traditional chemotherapies, and understanding the biology of the tumor is...

  • Characterization of a novel leucocyte activation antigen recognized by the antibody CMRF-37. Daish, A.; Hock, B. D.; Hart, D. N. J. // Immunology & Cell Biology;Feb1994, Vol. 72 Issue 1, p13 

    We describe a novel activation antigen recognized by the monoclonal antibody CMRF-37, which is absent or only weakly expressed on resting cells but is rapidly induced on T cells, B cells and monocytes following stimulation. Its kinetics of expression (12-24 h after the addition of the inductive...

  • Research Highlights. Aschheim, Kathy; DeFrancesco, Laura; Hare, Peter; Levinson, Ania; Theunissen, Jan-Willem // Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p307 

    The article reports on developments about research related to biotechnology as of March 2007. They include: Genentech researchers investigated whether a monoclonal antibody (mAb) targeting the neuropilin system might boost the efficacy of vascular endothelium growth factor mAbs, dendrimers can...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics